Collegium Pharmaceutical Inc (COLL) Stock Analysis
Verdict: WATCH (do not buy)
ADHD portfolio growth (JORNAY PM, AZSTARYS) is offset by Nucynta generic pricing pressure and $857.8M debt, making re-rating reliant on debt paydown.
Investment score: 52/100
Analysis as of
Is Collegium Pharmaceutical Inc stock worth reviewing? The TradeMates thesis
TradeMates evaluates Collegium Pharmaceutical as a WATCH candidate. Although trading at an attractive 3.17x EV/EBITDA with strong free cash flow generation ($327.6M in 2025), $857.8M in total debt and revenue headwinds from Nucynta generic pricing keep short-term upside capped until execution on the AZSTARYS integration is proven.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 58/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 52/100 (weight 15%)
Collegium Pharmaceutical Inc opportunities and risks
What speaks for COLL
- Rapid Expansion in the ADHD Franchise via JORNAY PM and AZSTARYS
What speaks against COLL
- Accelerated Pricing Pressure and Revenue Erosion in Legacy Pain Portfolio
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| COLL | 15.5x | 1.0x | 3.2x | 60.0% | 5.9% | 42.5% |
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.3% |
| ALMS | n/a | 119.0x | n/a | 88.2% | -5933.5% | -40.0% |
| ANRO | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.8% |
| LXRX | n/a | 16.4x | n/a | 98.9% | -147.4% | -11.7% |
| Peer median | n/a | 8.2x | n/a | 44.1% | -73.7% | -9.8% |
Frequently asked questions about Collegium Pharmaceutical Inc (COLL)
Is COLL stock a good investment?
The TradeMates model rates Collegium Pharmaceutical Inc as WATCH (do not buy) with an investment score of 52/100. TradeMates evaluates Collegium Pharmaceutical as a WATCH candidate. Although trading at an attractive 3.17x EV/EBITDA with strong free cash flow generation ($327.6M in 2025), $857.8M in total debt and revenue headwinds from Nucynta generic pricing keep short-term upside capped until execution on the AZSTARYS integration is proven. This is algorithmic model output, not personal investment advice.
Is COLL stock a buy?
The TradeMates model verdict for COLL is WATCH (do not buy) with an investment score of 52/100. Treat this as a model signal to review, not a personal buy recommendation.